Hopp til innhold
NHI.no
Annonse

Pemfigus: Årsaker

Innhold i artikkelen

Sykdommen skyldes autoantistoffer (proteiner i blodet) mot strukturer på celler i huden. Antistoffene forårsaker at cellene i overhuden blir skilt fra hverandre, og det dannes blærer i overhuden. De fleste tilfeller av pemfigus vulgaris og foliaceus oppstår spontant uten noen kjent underliggende årsak.

Annonse

I noen få tilfeller kan pemfigus være en reaksjon på medikamentbruk. Penicillamin (medikament mot revmatisme) og kaptopril (blodtrykksmedisin) kan gi pemfigusbilde.

Arveanlegg spiller sannsynligvis en rolle i enkelte tilfeller. Pemfigus kan finnes sammen andre sykdommer med unormal reaksjon i immunforsvaret. Ved enkelte godartede og ondartede svulster kan pemfigus også forekomme.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Pemfigus . Referanselisten for dette dokumentet vises nedenfor

  1. Bystryn J-C, Rudolph JL. Pemphigus. Lancet 2005; 366: 61-73. PubMed
  2. Meyerle JH, Anhalt GJ. Pemphigus. BestPractice, last updated January 2019.
  3. Langan SM, Smeeth L, Hubbard R et al. Bullous pemphigoid and pemphigus vulgaris - incidence and mortality in the UK: population based cohort study. BMJ 2008; 337: a180. PubMed
  4. Schwartz RA. Pemphigus foliaceus. Medscape, last updated Apr 03, 2018. emedicine.medscape.com
  5. Goldberg LJ. Paraneoplastic pemphigus. Medscape, last updated Feb 07, 2019. emedicine.medscape.com
  6. Estupiñan BA. IgA pemphigus. Medscape, last updated Apr 18, 2017. emedicine.medscape.com
  7. Zeina B. Pemphigus vulgaris. Medscape, last updated Jun 14, 2018. emedicine.medscape.com
  8. Hacker MK, Janson M, Fairley JA and Lin MS. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol 2002; 105: 64-74. PubMed
  9. Ruocco E, Aurilia A and Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001; 203: 201-7. PubMed
  10. Hale EK and Bystryn JC. Laryngeal and nasal involvement in pemphigus vulgaris. J Am Acad Dermatol 2001; 44: 609-11. PubMed
  11. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol 2011; 29:455. PubMed
  12. Ruocco E, Aurilia A and Ruocco V. Precautions and suggestions for pemphigus patients. Dermatology 2001; 203: 201-7. PubMed
  13. Hacker MK, Janson M, Fairley JA and Lin MS. Isotypes and antigenic profiles of pemphigus foliaceus and pemphigus vulgaris autoantibodies. Clin Immunol 2002; 105: 64-74. PubMed
  14. Harman KE, Albert S and Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-37. PubMed
  15. Bystryn JC. How should pemphigus be treated? Eur Acad Dermatol Venereol 2002; 16: 562-63. PubMed
  16. Mutasim DF. Management of autoimmune bullous diseases: pharmacology and therapeutics. J Am Acad Dermatol 2004; 51: 859-77. PubMed
  17. Yeh SW, Sami N, Ahmed RA. Treatment of pemphigus vulgaris: current and emerging options. Am J Clin Dermatol. 2005. 6(5):327-42.
  18. Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol 2011; 7: 529-41. pmid:21790294 PubMed
  19. Jiao D, Natow S and Bystryn JC. Treatment of pemphigus with IVIg. J Am Acad Dermatol 2002; 47: 358-63. PubMed
  20. Rutter A and Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44: 1010-23. PubMed
  21. Ahmed AR. Intravenous immunoglobulin therapy in the treatement of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679-90. PubMed
  22. Mertl M, Eming R. Management of refractory pemphigus vulgaris and pemphigus foliaceus. UpToDate, last updated Feb 06, 2015 . UpToDate
  23. Herbst A and Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 422-7. PubMed
Annonse
Annonse